PMID- 38065750
OWN - NLM
STAT- MEDLINE
DCOM- 20240408
LR  - 20240424
IS  - 1531-5037 (Electronic)
IS  - 0022-3468 (Linking)
VI  - 59
IP  - 4
DP  - 2024 Apr
TI  - Fish: A Promising Screening Tool for Malignancy After Augmentation Cystoplasty?
PG  - 725-730
LID - S0022-3468(23)00690-5 [pii]
LID - 10.1016/j.jpedsurg.2023.11.006 [doi]
AB  - INTRODUCTION: Malignancy after augmentation cystoplasty (AC) is reported up to 
      5.5 %. We assessed the use of urine fluorescence in situ hybridization (FISH) 
      screening for bladder malignancy after AC. PATIENTS AND METHODS: In this study, 
      36/98 patients under follow-up who have completed tenth year after ileal AC were 
      included prospectively. Twenty-four (66.7 %) patients were tested with FISH 
      initially and overall 28 (77.8 %) patients with conventional cytology (CC). 
      Twenty-four (66.7 %) patients with FISH analysis also had cytology analysis. 
      Blinded from the cytology results, 32 (88.9 %) patients who were consented 
      underwent cystoscopy with random biopsy (native bladder, ileal segment, 
      ileovesical junction). Two patients those were tested with FISH did not consented 
      cystoscopy. This study was registred to the government registry (No: 71146310). 
      RESULTS: Mean follow-up time after AC was 15.4 +/- 4.8 years. 2/32 (5.6 %) patients 
      were diagnosed with adenocarcinoma in cyctoscopic biopsy. FISH analysis of 3/24 
      (12.5 %) patients demonstrated abnormal findings consistent with malignancy. Two 
      FISH malignant patients were patients who had adenocarcinoma. The third patient's 
      biopsy was benign and the third year control cystoscopy was normal. 2/4 patients 
      with malignant CC had adenocarcinoma and 2/4 patients had benign biopsy. The 
      sensitivity and specificity of FISH in our series were 100 % and 95 % 
      respectively. Whereas the sensitivity and specificity of CC was 100 % and 91.6 % 
      respectively. CONCLUSION: Despite limited number of patients in this study, FISH 
      showed higher specificity than CC in this series. FISH is a promising tool for 
      malignancy screening after AC. TYPE OF STUDY: Diagnostic Studies. LEVEL OF 
      EVIDENCE: II.
CI  - Copyright (c) 2023 Elsevier Inc. All rights reserved.
FAU - Ceyhan, Erman
AU  - Ceyhan E
AD  - Hacettepe University Faculty of Medicine, Department of Urology, Ankara, Turkey. 
      Electronic address: erman_ceyhan@yahoo.com.
FAU - Mammadov, Emin
AU  - Mammadov E
AD  - Hacettepe University Faculty of Medicine, Department of Urology, Ankara, Turkey.
FAU - Onder, Sevgen Celik
AU  - Onder SC
AD  - Hacettepe University Faculty of Medicine, Department of Pathology, Ankara, 
      Turkey.
FAU - Dogan, Hasan Serkan
AU  - Dogan HS
AD  - Hacettepe University Faculty of Medicine, Department of Urology, Division of 
      Pediatric Urology, Ankara, Turkey.
FAU - Tekgul, Serdar
AU  - Tekgul S
AD  - Hacettepe University Faculty of Medicine, Department of Urology, Division of 
      Pediatric Urology, Ankara, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20231120
PL  - United States
TA  - J Pediatr Surg
JT  - Journal of pediatric surgery
JID - 0052631
SB  - IM
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Urinary Bladder/surgery
MH  - *Urinary Bladder Neoplasms/diagnosis/surgery/pathology
MH  - Cystoscopy
MH  - Sensitivity and Specificity
MH  - *Adenocarcinoma/pathology
OTO - NOTNLM
OT  - Adenocarcinoma
OT  - Biopsy
OT  - Cystoscopy
OT  - Fluorescent in situ hybridization
OT  - Urinary bladder
COIS- Conflicts of interest None.
EDAT- 2023/12/09 05:43
MHDA- 2024/04/08 06:42
CRDT- 2023/12/08 21:58
PHST- 2023/04/17 00:00 [received]
PHST- 2023/11/01 00:00 [revised]
PHST- 2023/11/10 00:00 [accepted]
PHST- 2024/04/08 06:42 [medline]
PHST- 2023/12/09 05:43 [pubmed]
PHST- 2023/12/08 21:58 [entrez]
AID - S0022-3468(23)00690-5 [pii]
AID - 10.1016/j.jpedsurg.2023.11.006 [doi]
PST - ppublish
SO  - J Pediatr Surg. 2024 Apr;59(4):725-730. doi: 10.1016/j.jpedsurg.2023.11.006. Epub 
      2023 Nov 20.